GLP-1 and MASLD/MASH: The Liver Disease Revolution Nobody's Talking About
Metabolic dysfunction-associated steatohepatitis (MASH) — formerly called NASH — affects an estimated 16 million Americans and is projected to become the leading cause of liver transplantation. Until 2024, there was no approved drug. Now there are two converging revolutions: resmetirom (Rezdiffra), approved March 2024 as the first dedicated MASH drug, and GLP-1 agonists, which are producing liver outcomes so dramatic they may redefine the treatment landscape.3,5
The Semaglutide Data
A Phase 2 trial of semaglutide in patients with biopsy-confirmed MASH showed MASH resolution (without worsening fibrosis) in 59% of patients on the highest dose versus 17% on placebo. Liver fat reduction was significant across all doses.1
Substudies from the FLOW trial (the semaglutide kidney outcomes trial) also showed substantial liver fat reduction in participants with metabolic dysfunction-associated steatotic liver disease (MASLD), though these were secondary analyses.4
The Survodutide Data: Best-in-Class for Liver
Survodutide, Boehringer Ingelheim's GLP-1/glucagon dual agonist, produced the most striking liver data in the pipeline. Phase 2 results published in the NEJM showed:2
| Endpoint | Survodutide (highest dose) | Placebo |
|---|---|---|
| MASH improvement (≥2-point NAS reduction) | 83% | ~18% |
| Liver fat reduction (MRI-PDFF) | 87% | ~20% |
| Fibrosis improvement (≥1 stage) | 64.5% | ~26% |
| Weight loss | ~19% | ~2% |
These numbers are remarkable. The 87% liver fat reduction and 83% MASH improvement represent efficacy levels that surpass resmetirom's Phase 3 data. The glucagon receptor activation in survodutide appears to provide additional hepatoprotective effects beyond what GLP-1 alone achieves — likely through enhanced hepatic fatty acid oxidation and improved mitochondrial function.2
GLP-1s vs. Resmetirom: Different Approaches
| Feature | GLP-1 Agonists | Resmetirom (Rezdiffra) |
|---|---|---|
| Mechanism | Appetite suppression + metabolic improvement | Thyroid hormone receptor-β agonist (liver-targeted) |
| Weight loss | 15–20% | Minimal (~1–2%) |
| MASH resolution | Up to 59% (sema), 83% (survodutide) | 25–30% (Phase 3) |
| Cardiovascular benefit | Yes (SELECT trial) | Not demonstrated |
| FDA approval for MASH | Not yet (liver-specific trials ongoing) | Yes (March 2024) |
| Addresses obesity | Yes | No |
The emerging picture is clear: GLP-1 agonists, particularly dual agonists with glucagon activity, may become first-line MASH treatment because they address both the liver disease and its primary driver (obesity). Resmetirom treats the liver without addressing weight — a meaningful limitation in a disease fundamentally linked to metabolic dysfunction.
SOURCES
- Newsome PN, et al. Semaglutide and MASH resolution: Phase 2 trial. Lancet Gastroenterol Hepatol. 2023.
- Loomba R, et al. Survodutide for MASH: Phase 2 NEJM data. NEJM. 2024.
- FDA. Resmetirom (Rezdiffra) approval for MASH. March 14, 2024.
- Harrison SA, et al. FLOW trial liver substudies.
- Rinella ME, et al. Nomenclature change: NAFLD→MASLD, NASH→MASH. Hepatology. 2023.